Zydus receives approval from COFEPRIS to market? Mamitra to treat various cancers
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
The inspections concluded with no Form 483 observations or significant critical findings
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software
Subscribe To Our Newsletter & Stay Updated